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This study aims to: estimate the prevalence of G2P[4] rotaviruses in Brazil between 2001–2011 from
patients with acute gastroenteritis; perform phylogenetic analyses of G2P[4] Brazilian strains (from vac-
cinated and non-vaccinated children) based on VP7 and VP8⁄ encoding genes and analyze the antigenic
regions of these proteins comparing with RV1; and assess the full genetic background of eleven selected
Brazilian strains. The G2P[4] detection rate among RVA positive samples was 0/157 in 2001, 3/226 (1.3%)
in 2002, 0/514 in 2003, 0/651 in 2004, 31/344 (9%)/2005, 112/227 (49%)/2006, 139/211 (66%)/2007, 240/
284 (85%)/2008, 66/176 (37.5%)/2009, 367/422 (87%)/2010 and 75/149 (50%)/2011. For the VP7 and VP8⁄
encoding genes, 52 sequences were analyzed and shared up to 99% nucleotide identity with other con-
temporary G2P[4] strains detected worldwide, grouping into different clusters. Most differences inside
antigenic epitopes of VP7 and VP8⁄ have been maintained in the G2P[4] Brazilian strains along the years,
and all were present before RV1 introduction. Eleven G2P[4] strains (4-vaccinated/7-non-vaccinated)
were completely characterized and possessed the typical DS-1-like genotype constellation (G2-P[4]-I2-
R2-C2-M2-A2-N2-T2-E2-H2) sharing up to 99% of nucleotide identity with contemporary worldwide
strains. Reassortments between Brazilian G2P[4] human strains were observed. In conclusion, the data
obtained in the current study suggests that implementation of RV1 vaccination might not inﬂuence
the genetic diversity observed in G2P[4] analyzed strains. Several factors might have contributed to
the increased prevalence of this genotype in Brazil since 2005: the introduction of RV1 into the Brazilian
National Immunization Program has resulted in a decrease in the relative prevalence of predominant
Wa-like RVA strains facilitating the increase of the heterotypic (DS-1-like) RVA strain G2P[4] in the
Brazilian population; the genetic diversity found in different geographical regions throughout the years
before, and after the introduction of RV1; the long period of low or no circulation of this genotype in
Brazil previous to RV1 introduction could have created favorable conditions for the accumulation of
immunological susceptible individuals.
 2014 Elsevier B.V. All rights reserved.1. Introduction
Group A rotaviruses (RVAs) were responsible for approximately
453,000 deaths worldwide among children 65 years old in 2008,mainly (>80%) in countries in Asia and Sub-Saharan Africa (Tate
et al., 2012). RVA belongs to the Reoviridae family and possesses
a segmented dsRNA genome (11 gene segments) encoding six
structural proteins (VP1-4, VP6-7) and six non-structural proteins
(NSP1-6). Based on their two outer capsid proteins, VP7 and VP4,
RVAs have been classiﬁed into G (Glycoprotein) and P (Protease-
sensitive) genotypes, respectively. Up-to-date there are 27 G types
and 37 P types reported (Matthijnssens et al., 2011; Trojnar et al.,
2013). However, the (intra-)genotype diversity can change from
one RVA season to the other and between different geographical
locations. In addition, sporadic emergence of novel strains and/or
Table 1
Detection rate of group A rotavirus (RVA) and prevalence of G2P[4] genotype per year
in Brazil.
Year Studied
samples, n
RVA-positive
samples, n (%)
G2P[4] detection rate among
RVA-positive samples, n (%)
2001 801 157 (19.6) 0 (0)
2002 840 226 (26.9) 3 (1.3)
2003 1856 514 (27.6) 0 (0)
2004 2544 651 (25.6) 0 (0)
2005 1292 344 (26.6) 31 (9)
2006 1576 227 (14.4) 112 (49.3)
2007 1232 211 (17.1) 139 (65.8)
2008 1013 284 (28) 240 (84.5)
2009 980 176 (17.9) 66 (37.5)
2010 1863 422 (22.6) 367 (86.9)
2011 1117 149 (13.3) 75 (50.3)
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(Santos and Hoshino, 2005; Leite et al., 2008; Matthijnssens and
Van Ranst, 2012).
The binary genotype classiﬁcation system has been extended
to the entire genome to better characterize RVA strains specifying
the genotype of all 11 genome segments (Matthijnssens et al.,
2011). Based on this classiﬁcation, most of the human RVA
detected worldwide possess either the Wa-like genotype constel-
lation (I1-R1-C1-M1-A1-N1-T1-E1-H1) or the DS-1-like genotype
constellation (I2-R2-C2-M2-A2-N2-T2-E2-H2) also called as
genotype 1 and 2, respectively (Heiman et al., 2008;
Matthijnssens et al., 2008; McDonald et al., 2009; Matthijnssens
and Van Ranst, 2012).
Universal vaccination against RVA has been considered strategic
in order to reduce both mortality and hospitalization due to diar-
rheal diseases, along with other measures such as oral rehydration,
breastfeeding, zinc administration and improvement of sanitation
in developing countries (WHO, 2013). In Brazil, RV1, an attenuated
human monovalent (G1P[8]) vaccine has been included in the
National Immunization Program (NIP) since March 2006. Ofﬁcial
data from the NIP indicated that vaccine coverage in Brazil ranged
between 46.5% (2006) and 87% (2011) (http://pni.datasus.gov.br/).
An increase in the relative frequency of G2P[4] RVAs occurred in
Brazil in the immediate post-vaccine years (Leite et al., 2008;
Carvalho-Costa et al., 2005; Correia et al., 2010; Dulgheroff et al.,
2012). As Brazil, Belgium and several Australian states imple-
mented the use of RV1 in the NIPs since 2006 and 2007, respec-
tively (Matthijnssens et al., 2012). After introduction of RV1, the
three countries shown a relative increase in strains with the
G2P[4] genotype compared with previous RVA seasons, and in
the case of Australia also compared with states using RV5 (Leite
et al., 2008; Correia et al., 2010; Carvalho-Costa et al., 2005;
Kirkwood et al., 2011; Dulgheroff et al., 2012; Matthijnssens
et al., 2012).
Some studies argued that both events, vaccine introduction and
increase prevalence of G2P[4], were associated suggesting that the
selective pressure generated by RV1 would select heterotypic
G2P[4] strain over (partially) homotypic G1P[8], G3P[8], G4P[8],
G9P[8] and G12P[8] RVA strains (Nakagomi et al., 2008; Gurgel
et al., 2009; Matthijnssens et al., 2012). However, other Latin
American countries that had not yet introduced universal vaccina-
tion also reported increased detection of G2P[4] at that time
(Amarilla et al., 2004; Ferrera et al., 2007; Patel et al., 2008). Con-
sequently, it has been suggested that this could be due to natural
genotype ﬂuctuation (Leite et al., 2008; Carvalho-Costa et al.,
2009, 2005; Matthijnssens et al., 2009). As described by
Matthijnssens et al. (2012), several factors might inﬂuence in
RVA genotype distribution, including natural factors (acquired
homotypic and heterotypic immunity, migration of people, emer-
gence of new RVA strain variants, genetic diversity present in a
particular genotype, among others) and the introduction of a RVA
vaccine into NIPs.
The evolving prevalence rates of different RVA genotypes during
and after vaccine introduction, as well as their epidemiological
characteristics are important issues and represent a challenge to
RVA vaccination programs. In this context, monitoring the emer-
gence of genotypes and escaping strains associated to break-
through infections is considered important in order to assess the
impact of universal vaccination in RVA circulating strains. In the
current study the prevalence of RVA genotype G2P[4] in Brazil
between 2005 and 2011 was assessed. Furthermore, G2P[4] strains
detected in the ﬁve regions of Brazil from 2005 to 2011 have been
analyzed for the VP7 and VP8⁄ encoding genes, and compared with
RVA strains available in the Genbank database, including the RV1
vaccine. The complete genome characterization of eleven G2P[4]
Brazilian selected strains was also performed.2. Material and methods
2.1. Laboratory based RVA surveillance and specimen collection
Laboratory based RVA surveillance was performed with fecal
deidentiﬁed samples obtained frompatientswith acute gastroenter-
itis. Samples were sent to the Regional Rotavirus Reference
Laboratory – Laboratory of Comparative andEnvironmental Virology
(RRRL-LVCA) by a network of state public health laboratories. These
labs, in turn, receive samples of health centers and hospitals in the
NationalHealth System.We studied samples from the followingBra-
zilian states: Acre (n = 372), Alagoas (n = 151), Amazonas (n = 6),
Bahia (n = 3495), Ceará (n = 667), Distrito Federal (n = 84), Espírito
Santo (n = 483), Goiás (n = 44), Maranhão (n = 557), Minas Gerais
(n = 373), Mato Grosso do Sul (n = 47), Mato Grosso (n = 3), Paraíba
(n = 25), Pernambuco (n = 195), Piauí (n = 1), Rio de Janeiro
(n = 4401), Rio Grande do Norte (n = 50), Rondônia (n = 51), Rio
Grande do Sul (n = 3197), Santa Catarina (n = 281), Sergipe (n = 631).
We studied 15,114 fecal samples, from which 3361 (22.2%)
were RVA-positive. Among RVA-positive patients, 361 were fully
(two doses of RV1) vaccinated children. Table 1 presents the
number of samples per year, the RVA detection rates and
prevalence of G2P[4] among RVA-positive patients.2.2. Group A rotavirus detection and G- and P-genotyping
In order to detect RVA in stool samples, polyacrylamide gel elec-
trophoresis (PAGE) (Pereira et al., 1983) and enzyme immunoassay
(EIA, Premier Rotaclone, Meridian Bioscience, Inc.; Ridascreen, R-
Biopharm), according to the manufacture’s protocols. Nucleic acid
was extracted from 10% fecal suspensions by the glass powder
method described by Boom et al. (1990), including modiﬁcations
as described by Gómez et al. (2013) and the QIAamp Viral RNAmini
kit (Qiagen/Westburg, TheNetherlands) according to themanufac-
turer’s instructions. In RVA-positive samples, the extractedRNAwas
reverse transcribed and G- and P-genotyping was performed using
semi-nested multiplex PCRs as previously described (WHO/IVB/
08.17, 2008). G and P RVA genotypeswere conﬁrmed by sequencing
for 52 samples. Criteria used to select these samples were: number
of positive samples per year (vaccinated and non-vaccinated),
amount of fecal sample, and quality of extracted RNA. In addition,
eleven selected strains representative from the surveillance period
(2005–2011), based on clusters observed in VP8⁄ and VP7 phyloge-
netic analysis, were investigated by whole genome analysis.2.3. Genome segments ampliﬁcation and sequencing
The ampliﬁcation of the eleven genome segments from selected
strains were performed using a OneStep RT-PCR Kit (QIAGEN)
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tion conditions: (i) for VP1-2: 50 C/30 min (min) – 95 C/15 min –
35 cycles of 94 C/30 s (sec)/45 C/30 s/72 C/6 min, 72 C/10 min;
(ii) VP3-4: annealing temperature changed to 47 C; (iii) for VP6,
VP7, NSP1-4: annealing temperature changed to 50 C (except for
NSP5, 45 C), and extension time to 3 min. Primers used to amplify
the 11 gene segments are listed in Supplementary Material 1. The
cDNA products were resolved on agarose gels electrophoresis and
puriﬁed using the ExoSAP-IT PCR Product Cleanup Kit (Affymetrix,
Miles Rd., Cleveland, OH, USA). Sequencing was performed with an
ABI Prism Big Dye Terminator Cycle Sequencing Ready Reaction
Kit™ on an ABI Prism 3730 Genetic Analyzer (Applied Biosystems,
Foster City, CA, USA) at the Instituto de Tecnologia em
Imunobiológicos (Bio-Manguinhos/FIOCRUZ), and an ABI Prism
3130 automated sequencer (Applied Biosystems, Foster City, CA,
USA) at the Rega Institute of Medical Research (University of
Leuven, Belgium).
2.4. Sequence and phylogenetic analysis
Sequences obtained in the current study were deposited in the
GenBank database under the following accession numbers:
KJ721696–KJ721783; KJ940055–KJ940118. Nucleotide BLAST
searches were performed and multiple sequence alignments were
carried out using the ClustalW program (Thompson et al., 1994).
Phylogenetic trees were constructed using the Neighbor-Joining
method with the Kimura-two parameter model in MEGA5.0
(Tamura et al., 2011). The statistical signiﬁcance of the branch
was assessed by bootstrap resampling analysis (2000 replicates).
Deduced amino acid sequences of the VP8⁄ and VP7 proteins of
the Brazilian G2P[4] RVA strains were compared with the RV1
strain, and RV5 strain (just VP7) using the Bioedit v.7.2.3 softwear
(Hall, 1999).
3. Results
3.1. RVA Surveillance and G2P[4] prevalence
The frequency of G2P[4] RVA detection between 2001 and 2003
was very low, more speciﬁcally only three of the analyzed samples
were positive for this genotype among 801 samples tested in 2001,
840 in 2002 and 1856 in 2003. During 2004, none of the 651 RVA
positive samples analyzed among the 2.554 patients with gastro-
enteritis belonged to this genotype. After 2004, the ﬁrst G2P[4]Fig. 1. Spatial spread of G2P[4] group A rotaviruses (RVA) in Brazil. The triangles indicate
in August/September 2005 (6 months before the implementation of universal vaccination
following years, G2P[4] spread in vast areas in many surveyed states. (For interpretatio
version of this article.)RVA samples detected in the RRRL-LVCA were in August, 2005 in
Western Brazil (Mato Grosso do Sul State), bordering Paraguay.
Between August and September 2005, 22 additional G2P[4] sam-
ples were detected in the same Brazilian region. In September
2005, seven G2P[4] samples were detected in the State of Acre
(Northern Brazil) bordering Bolivia. In December, 2005, one RVA
positive sample was characterized in Rio de Janeiro, the second
largest Brazilian city, which attracts people from Brazil and foreign
countries (Fig. 1). Therefore, the frequency of detection of G2P[4] in
2005 was 31 out of 344 RVA positive samples (9%) (Table 1).
In the post vaccination era, detection rates of G2P[4] among
RVA positive children with acute diarrheal disease were as follows:
112/227 (49%) in 2006, 139/211 (66%) in 2007, 240/284 (85%) in
2008, 66/176 (37.5%) in 2009, 367/422 (87%) in 2010 and 75/149
(50%) in 2011 (Table 1). Although the lower part of the 5570
Brazilian municipalities have been studied, and the cities surveyed
varied from year to year according to the demands of local health
authorities, it is observed that the proportion of municipalities
with detection of G2 increased between 2005 and 2008, decreasing
in 2009 and increasing again from 2010. As presented in Fig. 1,
G2P[4] has spread from Western cities to the majority of surveyed
municipalities from 2006 on. The proportion of surveyed munici-
palities with G2P[4] detection were as follows: 8 municipalities
with G2P[4] detection/98 surveyed municipalities (8%) in 2005,
24/164 (15%) in 2006, 35/137 (26%) in 2007, 70/173 (40%) in
2008, 22/146 (15%) in 2009, 86/222 (39%) in 2010 and 23/168
(14%) in 2011.
3.2. VP7 and VP8⁄ sequence and phylogenetic analysis
Fifty-two VP7 and VP8⁄/VP4 sequences (21 and 22 derived from
vaccinated children for VP7 and VP8⁄, respectively) were obtained
from children with acute gastroenteritis in 13 Brazilian states (four
Brazilian regions) between 2005 and 2011 (Supplementary
Material 2). Nucleotide and amino acid sequence identity among
Brazilian analyzed strains are shown in Table 2. Brazilian G2P[4]
obtained sequences shared a high level of nucleotide identity
(98–99%) with other G2P[4] strains detected worldwide in the last
decade, revealing a close phylogenetic relationship with such
strains, including strains previously reported in Brazil (Gómez
et al., 2005).
VP7 phylogenetic analysis revealed that all G2P[4] Brazilian
strains analyzed belonged to lineage II, and grouped in several
clusters: (a) strains detected between 2005 and 2007 in thethe cities where G2P[4] strains were detected. The ﬁrst G2P[4] strains were detected
) in western states and in December 2005 in Rio de Janeiro city (red triangles). In the
n of the references to color in this ﬁgure legend, the reader is referred to the web
Table 2
Nucleotide (nt) and amino acid (aa) identity values among Brazilian G2P[4] group A
rotavirus (RVA) strains analyzed in the current study. Values for VP7 and VP8⁄ are
based on all the RVA Brazilian strains analyzed in the current study, while values for
the rest of the genes/proteins (NSP1-5, VP1-4, and VP6) are based on the RVA
Brazilian strains from which all 11 genes were obtained.
Encoding gene % nt identity % aa identity
VP7 95.9–100 97.2–100
VP8⁄ 96.7–100 96.8–100
NSP1 96.9–100 96.7–100
NSP2 97.1–99.8 97.1–100
NSP3 97.4–100 97.7–100
NSP4 88.2–99.7 96.5–99.4
NSP5 97.2–100 99–100
VP1 94.8–99.7 98.6–99.7
VP2 97.6–99.8 99.1–100
VP3 87.3–99.9 93–100
VP4 97.5–99.7 98.7–99.7
VP6 96.7–99.9 98.9–100
VP7
 RVA/Human-wt/BRA/RJ13393/2007/G2P[4]
 RVA/Human-wt/BRA/RJ13561/2007/G2P[4]
 RVA/Human-wt/BRA/15786 08ES/2008/G2P[4]
 RVA/Human-wt/BRA/13780 07RJ/2007/G2P[4]
 RVA/Human-wt/BRA/13793 07SE/2007/G2P[4]
 RVA/Human-wt/BRA/13158 06ES/2006/G2P[4]
 RVA/Human-wt/BRA/15774 08PE/2008/G2P[4]
 RVA/Human-wt/BRA/SE13801/2007/G2P[4]
 RVA/Human-wt/BRA/RJ12225/2006/G2P[4]
 RVA/Human-wt/BRA/AL15603/2008/G2P[4]
 RVA/Human-wt/BRA/13788 07SE/2007/G2P[4]
 RVA/Human-wt/BRA/12549 06RJ/2006/G2P[4]
 RVA/Human-wt/BRA/RJ12209/2006/G2P[4]
 RVA/Human-wt/BRA/RJ12398/2006/G2P[4]
 RVA/Human-wt/BRA/SE17227/2009/G2P[4]
 RVA/Human-wt/BRA/15385 08BA/2008/G2P[4]
 RVA/Human-wt/BRA/BA15626/2008/G2P[4]
 RVA/Human-wt/BRA/MA19557/2011/G2P[4]
 RVA/Human-wt/BRA/15811 08SE/2008/G2P[4]
 RVA/Human-wt/BRA/RS15633/2008/G2P[4]
 RVA/Human-wt/BRA/RS15851/2008/G2P[4]
 RVA/Human-wt/BRA/14422 07RS/2007/G2P[4]
 RVA/Human-wt/BRA/RJ16581/2009/G2P[4]
e
 RVA/Human-wt/BRA/MA19112/2010/G2P[4]
 RVA/Human-wt/BRA/15863 08MA/2008/G2P[4]
 RVA/Human-wt/BRA/16054 09MA/2009/G2P[4]
 RVA/Human-wt/USA/2007719869/2007/G2P[4]
 RVA/Human-wt/BRA/MG19041/2010/G2P[4]
 RVA/Human-wt/BRA/RJ17745/2010/G2P[4]
 RVA/Human-wt/BRA/RJ18346/2010/G2P[4]
 RVA/Human-wt/BRA/SE19297/2010/G2P[4]
 RVA/Human-wt/BRA/SE18265/2010/G2P[4]
 RVA/Human-wt/BRA/ES19071/2010/G2P[4]
 RVA/Human-wt/BRA/ES19072/2010/G2P[4]
d
 RVA/Human-wt/THA/CMH028/2007/G2P[X]
 RVA/Human-wt/USA/VU08-09-38/2008/G2P[4]
 RVA/Human-wt/BGD/MMC84/2005/G2P[4]
 RVA/Human-wt/BGD/MMC6/2005/G2P[4]
 RVA/Human-wt/BRA/RS13903/2007/G2P[4]
 RVA/Human-wt/BRA/RS13898/2007/G2P[4]
 RVA/Human-wt/BRA/14157 07RS/2007/G2P[4]
 RVA/Human-wt/USA/VU08-09-8/2008/G2P[4]/[8]
 RVA/Human-wt/USA/VU08-09-35/2008/G2P[4]
 RUSSIA 2008-2012 G2P[4]
b
 RVA/Human-wt/BRA/BA18480/2010/G2P[4]
 RVA/Human-wt/BRA/SE20079/2011/G2P[4]
 RVA/Human-wt/BRA/PE19840/2011/G2P[4]
 RVA/Human-wt/BRA/BA17990/2010/G2P[4]
 RVA/Human-wt/BRA/16099 09ES/2009/G2P[4]
 RVA/Human-wt/BRA/15782 08MG/2008/G2P[4]
 RVA/Human-wt/BRA/15860 08RJ/2008/G2P[4]
 RVA/Human-wt/BRA/ES16238/2009/G2P[4]
 RVA/Human-wt/ITA/PA133/2011/G2P[4]
 RVA/Human-wt/BRA/BA16954/2009/G2P[4]
 RVA/Human-wt/ITA/PA83/2007/G2P[4]
 RVA/Human-wt/AUS/CK20024/2006/G2P[4]
 RVA/Human-wt/RUS/Omsk07-87/2007/G2P[4]
 RVA/Human-wt/BRA/MG19243/2010/G2P[4]
 RVA/Human-wt/BRA/RS18922/2010/G2P[4]
 RVA/Human-wt/BRA/RS18923/2010/G2P[4]
 RVA/Human-wt/BRA/RS18917/2010/G2P[4]
 RVA/Human-wt/BRA/RS18326/2010/G2P[4]
 RVA/Human-wt/BRA/SC19868/2011/G2P[4]
 RVA/Human-wt/BRA/SC18536/2010/G2P[4]
 RVA/Human-wt/BRA/SE19300/2010/G2P[4]
c
 RVA/Human-wt/CIV/CI1735/1999/G2P[4]
 RVA/Human-wt/RUS/Nov04-H391/2004/G2P[4]
 RVA/Human-wt/KOR/KMR750/2001/G2P[4]
 RVA/Human-wt/KOR/KMR126/2004/G2P[4]
 RVA/Human-wt/BRA/MA14286/2007/G2P[4]
 RVA/Human-wt/BRA/MA14285/2007/G2P[4]
 RVA/Human-wt/BRA/RS13086/2006/G2P[4]
 RVA/Human-wt/THA/CU497-BK/2009/G2P[4]
 RVA/Human-wt/THA/CU473-BK/2009/G2P[4]
 RVA/Human-wt/THA/CU438-KK/2009/G2P[4]
 RVA/Human-wt/THA/CU382-BK/2008/G2P[4]
 RVA/Human-wt/THA/CU379-BK/2008/G2P[4]
 RVA/Human-wt/BRA/11143 05MS/2005/G2P[4]
 RVA/Human-wt/BRA/11580 05AC/2005/G2P[4]
 RVA/Human-wt/BRA/MS11264/2005/G2P[4]
 RVA/Human-wt/BRA/MS11266/2005/G2P[4]
 RVA/Human-wt/BRA/MS11142/2005/G2P[4]
 RVA/Human-wt/BRA/MS11271/2005/G2P[4]
 RVA/Human-wt/BRA/MS11262/2005/G2P[4]
 RVA/Human-wt/USA/VU05-06-66/2005/G2P[4]
 RVA/Human-wt/USA/VU06-07-36/2006/G2P[4]
 RVA/Human-wt/BRA/MT11258/2005/G2P[4]
a
 RVA/Human-wt/CHN/TB-Chen/1996/G2P[4]
Lineage II
 RVA/Human-tc/USA/DS-1/1976/G2P[4]
 RVA/Human-wt/AUS/CK20001/1977/G2P[4] Lineage I
 RVA/Human-wt/BRA/RJ5619/2002/G2P[4]
 RVA/Human-tc/KEN/AK26/1982/G2P[4]
 RVA/Vaccine/USA/RotaTeq-SC2-9/1992/G2P[5]
Lineage III
 RVA/Vaccine/USA/Rotarix-A41CB052A/1988/G1P[8]
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Fig. 2. Phylogenetic analyses based on VP7 and VP8⁄ nucleotide sequences from Brazil
strains available from GenBank. Brazilian G2P[4] strains analyzed in the current study
Bootstrap values under 70% are not shown. G2 and P[4] lineages are shown at the right-h
per site.
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cyan); (b) strains detected in 2007 in Rio Grande do Sul state
(Southern Brazil) (colored in violet); (c) strains detected between
2009 and 2011 in the Southeastern, Northeastern and Southern
regions (colored in blue); (d) strains detected in 2010 in the North-
eastern and Southeastern regions (colored in orange); (e) strains
detected between 2006 and 2009, and in 2011 in the Southeastern,
Northeastern and Southern regions (colored in red) (Fig. 2).
VP8⁄ phylogenetic analysis revealed that all studied strains
belonged to lineage V (Fig. 2). Furthermore, Brazilian G2P[4]
strains analyzed in the current study grouped into several clusters
formed by: (a) strains detected throughout the entire study period
in Southeastern, Northeastern, Central Western and Southern
regions; (b) strains detected in 2007 in Rio Grande do Sul state
(Southern); (c) strains detected between 2009 and 2011 in the
Southeastern, Northeastern and Southern regions; (d) strains RVA/Human-wt/BRA/PB16816/2009/G2P[4]
 RVA/Human-wt/ITA/PA83/2007/G2P[4]
 RVA/Human-wt/BRA/15859 08MG/2008/G2P[4]
 RVA/Human-wt/RUS/Omsk08-408/2008/G2P[4]
 RVA/Human-wt/BRA/PE17886/2010/G2P[4]
 RVA/Human-wt/BRA/16100 09ES/2009/G2P[4]
 RVA/Human-wt/BRA/ES16238/2009/G2P[4]
 RVA/Human-wt/BRA/BA18480/2010/G2P[4]
 RVA/Human-wt/BRA/BA17990/2010/G2P[4]
 RVA/Human-wt/BRA/SE20079/2011/G2P[4]
 RVA/Human-wt/ITA/PA130/2010/G2P[4]
 RVA/Human-wt/BRA/15900 08MG/2008/G2P[4]
 RVA/Human-wt/AUS/CK20032/2006/G2P[4]
 RVA/Human-wt/RUS/Nov05-137/2005/G2P[4]
 RVA/Human-tw/RUS/Omsk07-83/2007/G2P[4]
 RVA/Human-wt/RUS/Omsk07-83/2007/G2P[4]
 RVA/Human-wt/RUS/Omsk07-87/2007/G2P[4]
 RVA/Human-wt/BRA/RS18326/2010/G2P[4]
 RVA/Human-wt/BRA/MG19243/2010/G2P[4]
 RVA/Human-wt/BRA/RS18922/2010/G2P[4]
 RVA/Human-wt/BRA/SC18536/2010/G2P[4]
 RVA/Human-wt/BRA/PE19772/2011/G2P[4]
 RVA/Human-wt/BRA/AL18871/2010/G2P[4]
 RVA/Human-wt/BRA/SE19300/2010/G2P[4]
 RVA/Human-wt/BRA/PE19841/2011/G2P[4]
c
 RVA/Human-wt/ITA/PA133/2011/G2P[4]
 RVA/Human-wt/THA/CMH070/2007/G2P[4]
 RVA/Human-wt/RUS/Nov04-H676/2004/G2P[4]
 RVA/Human-wt/THA/CU209-KK/2008/G2P[4]
 RVA/Human-wt/IND/mcs65/2011/G8P[4]
 RVA/Human-wt/IND/mcs63/2011/G8P[4]
 RVA/Human-wt/BRA/RJ18346/2010/G2P[4]
 RVA/Human-wt/BRA/MG19041/2010/G2P[4]
 RVA/Human-wt/BRA/RJ17745/2010/G2P[4]
 RVA/Human-wt/BRA/MA19112/2010/G2P[4]
 RVA/Human-wt/USA/2007719869/2007/G2P[4]
 RVA/Human-wt/BRA/SE18265/2010/G2P[4]
 RVA/Human-wt/BRA/ES19071/2010/G2P[4]
 RVA/Human-wt/BRA/ES19072/2010/G2P[4]
d
 RVA/Human-wt/USA/VU05-06-54/2005/G2P[4]
 RVA/Human-wt/BRA/12842 06ES/2006/G2P[4]
 RVA/Human-wt/RUS/Nov04-H431/2004/G2P[4]
 RVA/Human-wt/THA/CMH028/2007/G2P[4]
 RVA/Human-wt/THA/CMH043/2007/G2P[4]
 RVA/Human-wt/THA/CMH049/2007/G2P[4]
 RVA/Human-wt/USA/2008747095/2008/G2P[4]
 RVA/Human-xx/RUS/Nov09-D1/2009/G2P[4]
 RVA/Human-wt/BRA/RS13898/2007/G2P[4]
 RVA/Human-wt/BRA/RS13903/2007/G2P[4]
b
 RVA/Human-wt/ITA/PA150/2006/G2P[4]
 RVA/Human-wt/RUS/Nov04-H391/2004/G2P[4]
 RVA/Human-wt/BRA/AL15598/2008/G2P[4]
 RVA/Human-wt/BRA/15777 08PE/2008/G2P[4]
 RVA/Human-wt/BRA/AL15603/2008/G2P4
 RVA/Human-wt/BRA/14422 07RS/2007/G2P[4]
 RVA/Human-wt/BRA/RJ16581/2009/G2P[4]
 RVA/Human-wt/BRA/13788 07SE/2007/G2P[4]
 RVA/Human-wt/BRA/RJ12398/2006/G2P[4]
 RVA/Human-wt/BRA/RJ12209/2006/G2P[4]
 RVA/Human-wt/BRA/RJ12225/2006/G2P[4]
 RVA/Human-wt/BRA/SE13801/2007/G2P[4]
 RVA/Human-wt/BRA/14303 07MG/2007/G2P[4]
 RVA/Human-wt/BRA/RJ13393/2007/G2P[4]
 RVA/Human-wt/BRA/RJ13561/2007/G2P[4]
 RVA/Human-wt/BRA/RS18622/2010/G2P[4]
 RVA/Human-wt/BRA/PE19840/2011/G2P[4]
 RVA/Human-wt/BRA/SC19868/2011/G2P[4]
 RVA/Human-wt/BRA/RS18380/2010/G2P[4]
 RVA/Human-wt/BRA/RS18917/2010/G2P[4]
 RVA/Human-wt/BRA/RS18918/2010/G2P[4]
 RVA/Human-wt/BRA/SC18412/2010/G2P[4]
 RVA/Human-wt/BRA/15774 08PE/2008/G2P[4]
 RVA/Human-wt/BRA/13668 07AL/2007/G2P[4]
 RVA/Human-wt/BRA/RS13086/2006/G2P[4]
 RVA/Human-wt/BRA/RJ12389/2006/G2P[4]
 RVA/Human-wt/THA/CU436-KK/2009/G2P[4]
 RVA/Human-wt/BRA/SE17227/2009/G2P[4]
 RVA/Human-wt/BRA/MT11258/2005/G2P[4]
 RVA/Human-wt/BRA/11257 05MS/2005/G2P[4]
 RVA/Human-wt/BRA/MA14286/2007/G2P[4]
 RVA/Human-wt/BRA/11580 05AC/2005/G2P[4]
 RVA/Human-wt/BRA/RS15851/2008/G2P[4]
 RVA/Human-wt/BRA/RO13269/2006/G2P[4]
 RVA/Human-wt/BRA/15811 08SE/2008/G2P[4]
 RVA/Human-wt/AUS/CK20034/2006/G2P[4]
 RVA/Human-wt/BRA/12482 06BA/2006/G2P[4]
 RVA/Human-wt/BRA/12287 06BA/2006/G2P[4]
 RVA/Human-wt/BRA/MA19557/2011/G2P[4]
 RVA/Human-wt/BRA/MS11142/2005/G2P[4]
 RVA/Human-wt/BRA/11860 06RJ/2006/G2P[4]
 RVA/Human-wt/BRA/MS11264/2005/G2P[4]
 RVA/Human-wt/BRA/MS11271/2005/G2P[4]
 RVA/Human-wt/BRA/MS11262/2005/G2P[4]
 RVA/Human-wt/BRA/11143 05MS/2005/G2P[4]
a
Lineage V
Lineage I RVA/Human-tc/USA/DS-1/1976/G2P[4]
 RVA/Human-tc/KEN/AK26/1982/G2P[4]
 RVA/Human-wt/BRA/RJ5619/2002/G2P[4] Lineage IV
Lineage III RVA/Human-tc/PHL/L26/1987/G12P[4]
 RVA/Human-wt/MAW/MW333/XXXX/G8P[4]
 RVA/Human-wt/BRA/5877 02RJ/2002/G8P[4]
 RVA/Human-wt/BRA/5664 02RJ/2002/G8P[4]
Lineage II
 RVA/Human-tc/USA/Wa/1974/G1P[8]
 RVA/Vaccine/USA/Rotarix-A41CB052A/1988/G1P[8]
100
88
100
87
76
99
96
92
87
80
98
99
73
85
87
99
0.05
P8*
ian G2P[4] strains detected between 2005 and 2011, and group A rotavirus (RVA)
are colored, and strains from vaccinated children are marked with a ﬁlled circle.
and side of each phylogenetic tree. Scale bars represent 0.05 nucleotide substitution
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(Fig. 2).
Phylogenetic analysis based on VP7 and VP8⁄ encoding genes
suggested the occurrence of reassortment among G2P[4] Brazilian
analyzed strains colored in red, blue and cyan (Fig. 2).
Comparison of the deduced amino acid sequences of VP7
Brazilian G2P[4] strains and the RV1 strain revealed that
Brazilian G2P[4] strains showed amino acid substitutions inside
antigenic epitopes at positions, as well as when comparing with
RV5 G2 strain, showing 38% and 86–93% of identity, respec-
tively (Fig. 3).
As observed for VP7, Brazilian G2P[4] strains showed the amino
acid substitutions inside antigenic epitopes of VP8 protein when
comparing with RV1 strain revealing 42–50% (Brazilian G2P[4]
strains that grouped inside cluster ‘‘a’’, ‘‘b’’, and ‘‘c’’) and 54% (Bra-
zilian G2P[4] strains that grouped inside cluster ‘‘d’’) of amino acid
identity with RV1 (Fig. 3).
RVA detected from vaccinated and non-vaccinated children
shared the same amino acid differences when compared with
RV1 strain for both proteins analyzed.Fig. 3. Alignment of the deduced amino acid sequences inside antigenic epitopes of VP7 a
RV1 and RV5 G2 strains (VP7). Amino acid differences are indicated with a grey shadow
Table 3
Genomic background of RV1, RV5, and G2P[4] Brazilian group A rotavirus (RVA) strains.
genotypes in italic were obtained with partial sequences.
VP7 VP4 V
G1 P[8]
G1 P[5]
G2 P[5]
G3 P[5]
G4 P[5]
G6 P[8]
VP7 VP4 V
G2 P[4]
G2 P[4]
G2 P[4]
G2 P[4]
G2 P[4]
G2 P[4]
G2 P[4]
G2 P[4]
G2 P[4]
G2 P[4]
G2 P[4]
Strain
RVA/Vaccine/USA/RotaTeq-BrB-9/1996/G4P[5]
RVA/Vaccine/USA/RotaTeq-WI79-4/1992/G6P[8]
RVA/Human-wt/BRA/ES16238/2009/G2P[4]
RVA/Human-wt/BRA/RS15851/2008/G2P[4]
RVA/Vaccine/USA/Rotarix-A41CB052A/1988/G1P[8]
RVA/Vaccine/USA/RotaTeq-WI79-9/1992/G1P[5]
RVA/Vaccine/USA/RotaTeq-SC2-9/1992/G2P[5]
RVA/Vaccine/USA/RotaTeq-WI78-8/1992/G3P[5]
RVA/Human-wt/BRA/MA19557/2011/G2P[4]*
RVA/Human-wt/BRA/SC19868/2011/G2P[4]*
RVA/Human-wt/BRA/SE19300/2010/G2P[4]
RVA/Human-wt/BRA/RJ17745/2010/G2P[4]*
RVA/Human-wt/BRA/MA14286/2007/G2P[4]*
RVA/Human-wt/BRA/SE13801/2007/G2P[4]
RVA/Human-wt/BRA/RJ12225/2006/G2P[4]
RVA/Human-wt/BRA/RS13086/2006/G2P[4]
RVA/Human-wt/BRA/MS11142/2005/G2P[4]3.3. Whole-genome characterization of G2P[4] Brazilian strains
Eleven G2P[4] Brazilian strains, representative of the different
clusters observed when analyzing the VP7 and VP8⁄ encoding
genes, and with sufﬁcient stool material, were selected to perform
complete genome analysis. Four of these strains were detected in
vaccinated children, and seven in unvaccinated children and all
were hospitalized with acute gastroenteritis between 2005 and
2011.
All analyzed strains showed a I2-R2-C2-M2-A2-N2-T2-E2-H2
genomic background (Table 3). Although all strains displayed the
same genotype constellation, different genetic variants of circulat-
ing G2P[4] strains during the study period in Brazil were observed
(Figs. 4 and 5).
The majority of the G2P[4] Brazilian strains analyzed in the cur-
rent study (colored in red) showed close phylogenetic relationship
with G2P[4] human strains detected mainly in Australia (1999,
2000, 2007), USA (2005, 2007), Italy (2006), and Thailand (2009)
(Figs. 4 and 5). In addition, strains RVA/Human-wt/BRA/ES16238/
2009/G2P[4], RVA/Human-wt/BRA/SE19300/2010/G2P[4] (colorednd VP8⁄ proteins of Brazilian G2P[4] strains analyzed compared with reference DS-1,
.
Brazilian G2P[4] strains from vaccinated children are marked with an asterisk, and
P6 VP1 VP2 VP3 NSP1 NSP2 NSP3 NSP4 NSP5
I1 R1 C1 M1 A1 N1 T1 E1 H1
I2 R2 C2 M1 A3 N2 T6 E2 H3
I2 R2 C2 M1 A3 N2 T6 E2 H3
I2 R2 C2 M2 A3 N2 T6 E2 H3
I2 R2 C2 M2 A3 N2 T6 E2 H3
I2 R2 C2 M2 A3 N2 T6 E2 H3
P6 VP1 VP2 VP3 NSP1 NSP2 NSP3 NSP4 NSP5
I2 R2 C2 M2 A2 N2 T2 E2 H2
I2 R2 C2 M2 A2 N2 T2 E2 H2
I2 R2 - M2 A2 N2 T2 E2 H2
I2 R2 C2 M2 A2 N2 T2 E2 H2
I2 R2 C2 M2 A2 N2 T2 E2 H2
I2 R2 C2 M2 A2 N2 T2 E2 H2
I2 R2 C2 M2 A2 N2 T2 E2 H2
I2 R2 C2 M2 A2 N2 T2 E2 H2
I2 R2 C2 M2 A2 N2 T2 E2 H2
I2 R2 C2 M2 A2 N2 T2 E2 H2
I2 R2 C2 M2 A2 N2 T2 E2 H2
RVA Vaccines Genomic Background
Brazilian G2P[4] Genomic Background
 RVA/Human-wt/ITA/PA108/2007/G2P[4]
 RVA/Human-wt/BGD/MMC88/2005/G2P[4]
 RVA/Human-wt/USA/VU08-09-38/2008/G2P[4]
 RVA/Human-wt/USA/2007719869/2007/G2P[4]
 RVA/Human-wt/BRA/RJ17745/2010/G2P[4]
 RVA/Human-wt/IDN/BL-5210/2006/G2P[4]
 RVA/Human-wt/AUS/CK20048/2011/G2P[4]
 RVA/Human-wt/ITA/PA17/2008/G2P[4]
 RVA/Human-wt/AUS/SA066/2010/G2P[4]
 RVA/Human-wt/AUS/CK20059/2010/G2P[4]
 RVA/Human-wt/USA/VU10-11-24/2011/G2P[4]
 RVA/Human-wt/ITA/PA133/2011/G2P[4]
 RVA/Human-wt/BRA/ES16238/2009/G2P[4]
 RVA/Human-wt/USA/VU08-09-13/2008/G2P[4]
 RVA/Human-wt/USA/VU08-09-11/2008/G2P[4]
 RVA/Human-wt/USA/VU10-11-19/2011/G2P[4]
 RVA/Human-wt/AUS/CK20042/2010/G2P[4]
 RVA/Human-xx/AUS/WAPC703/2010/G2P[4]
 RVA/Human-wt/GR 10924/1999/G9P[6]
 RVA/Human-wt/RUS/Nov04-H391/2004/G2P[4]
 RVA/Human-wt/ITA/PA150/2006/G2P[4]
 RVA/Human-wt/USA/LB2772/2005/G2P[4]
 RVA/Human-wt/USA/VU05-06-66/2005/G2P[4]
 RVA/Human-wt/AUS/CK20036/2007/G2P[4]
 RVA/Human-wt/USA/VU10-11-21/2011/G2P[4]
 RVA/Human-wt/USA/2007719874/2007/G2P[4]
 RVA/Human-wt/BRA/MS11142/2005/G2P[4]
 RVA/Human-wt/BRA/SE13801/2007/G2P[4]
 RVA/Human-wt/BRA/RJ12225/2006/G2P[4]
 RVA/Human-wt/BRA/RS13086/2006/G2P[4]
 RVA/Human-wt/BRA/MA14286/2007/G2P[4]
 RVA/Human-wt/BRA/MA19557/2011/G2P[4]
 RVA/Human-wt/BRA/RS15851/2008/G2P[4]
 RVA/Human-wt/ITA/PA83/2007/G2P[4]
 RVA/Human-wt/BRA/SC19868/2011/G2P[4]
 RVA/Human-wt/BRA/SE19300/2010/G2P[4]
 RVA/Human-wt/RUS/Nov04-H390/2004/G2P[4]
 RVA/Human-xx/RUS/Nov11-N2246/2011/G2P[8]
 RVA/Human-wt/AUS/CK20024/2006/G2P[4]
 RVA/Human-tc/USA/DS-1/1976/G2P[4]
 RVA/Human-wt/CHN/TB-Chen/1996/G2P[4]
N2
 RVA/Human-tc/USA/Wa/1974/G1P[8]
 RVA/Human-tc/CHN/L621/2006/G3P[9]
99
99
87
79
98
99
96
97
94
88
75
97
89
89
99
87
76
85
71
88
0.05
 RVA/Human-wt/ITA/PA130/2010/G2P[4]
 RVA/Human-wt/AUS/CK20027/2006/G2P[4]
 RVA/Human-xx/AUS/MON008/2010/G2P[4]
 RVA/Human-wt/USA/2008747095/2008/G2P[4]
 RVA/Human-wt/USA/VU10-11-24/2011/G2P[4]
 RVA/Human-wt/BGD/MMC88/2005/G2P[4]
 RVA/Human-wt/ITA/PA108/2007/G2P[4]
 RVA/Human-wt/USA/VU10-11-19/2011/G2P[4]
 RVA/Human-wt/THA/CU110-BK/2008/G2P[4]
 RVA/Human-wt/BRA/RJ17745/2010/G2P[4]
 RVA/Human-wt/USA/2007719869/2007/G2P[4]
 RVA/Human-wt/AUS/SA066/2010/G2P[4]
 RVA/Human-wt/AUS/CK20058/2010/G2P[4]
 RVA/Human-wt/ITA/PA17/2008/G2P[4]
 RVA/Human-wt/BRA/ES16238/2009/G2P[4]
 RVA/Human-wt/ITA/PA133/2011/G2P[4]
 RVA/Human-wt/BGD/MMC6/2005/G2P[4]
 RVA/Human-wt/BRA/SE13801/2007/G2P[4]
 RVA/Human-wt/BRA/RJ12225/2006/G2P[4]
 RVA/Human-wt/ITA/PA83/2007/G2P[4]
 RVA/Human-wt/BRA/SE19300/2010/G2P[4]
 RVA/Human-xx/AUS/RCH041/2010/G2P[4]
 RVA/Human-wt/ITA/PA84/2008/G2P[4]
 RVA/Human-wt/AUS/V233/1999/G2P[4]
 RVA/Human-wt/ITA/PA3/2004/G2P[4]
 RVA/Human-wt/ITA/PA150/2006/G2P[4]
 RVA/Human-wt/USA/VU10-11-21/2011/G2P[4]
 RVA/Human-wt/BRA/MA19557/2011/G2P[4]
 RVA/Human-wt/BRA/RS15851/2008/G2P[4]
 RVA/Human-wt/USA/VU05-06-66/2005/G2P[4]
 RVA/Human/CHN/CC0812-2/2008/G2P[X]
 RVA/Human-xx/CHN/CC0812-2/2008/G2P[X]
 RVA/Human-wt/THA/CU473-BK/2009/G2P[4]
 RVA/Human-wt/BRA/SC19868/2011/G2P[4]
 RVA/Human-wt/BRA/MS11142/2005/G2P[4]
 RVA/Human-wt/BRA/MA14286/2007/G2P[4]
 RVA/Human-wt/BRA/RS13086/2006/G2P[4]
 RVA/Human-wt/CHN/TB-Chen/1996/G2P[4]
 RVA/Human-tc/KEN/AK26/1982/G2P[4]
 RVA/Human-tc/USA/DS-1/1976/G2P[4]
 RVA/Human-wt/AUS/CK20001/1977/G2P[4]
 RVA/Human-tc/USA/Wa/1974/G1P[8]
 RVA/Human-tc/CHN/L621/2006/G3P[9]
96
95
99
89
96
99
98
84
81
86
99
99
99
86
80
70
77
84
0.05
A2
 RVA/Human-wt/USA/VU10-11-21/2011/G2P[4]
 RVA/Human-wt/USA/VU10-11-24/2011/G2P[4]
 RVA/Human-wt/USA/VU08-09-11/2008/G2P[4]
 RVA/Human-wt/BGD/MMC88/2005/G2P[4]
 RVA/Human-wt/AUS/CK20057/2010/G2P[4]
 RVA/Human-wt/AUS/CK20044/2010/G2P[4]
 RVA/Human-wt/ITA/PA108/2007/G2P[4]
 RVA/Human-wt/ITA/PA17/2008/G2P[4]
 RVA/Human-wt/USA/VU10-11-19/2011/G2P[4]
 RVA/Human-wt/BRA/SE13801/2007/G2P[4]
 RVA/Human-wt/BRA/RJ12225/2006/G2P[4]
 RVA/Human-wt/BRA/MA19557/2011/G2P[4]
 RVA/Human-wt/BRA/RS15851/2008/G2P[4]
 RVA/Human-wt/BRA/RJ17745/2010/G2P[4]
 RVA/Human-wt/USA/2007719869/2007/G2P[4]
 RVA/Human-wt/AUS/CK20018/2000/G2P[4]
 RVA/Human-wt/AUS/V233/1999/G2P[4]
 RVA/Human-wt/ITA/PA150/2006/G2P[4]
 RVA/Human-wt/USA/LB2744/2005/G2P[4]
 RVA/Human-wt/USA/2007719874/2007/G2P[4]
 RVA/Human-wt/BRA/MA14286/2007/G2P[4]
 RVA/Human-wt/BRA/RS13086/2006/G2P[4]
 RVA/Human-wt/BRA/MS11142/2005/G2P[4]
 RVA/Human-wt/AUS/CK20036/2007/G2P[4]
 RVA/Human-wt/USA/VU05-06-66/2005/G2P[4]
 RVA/Human-wt/USA/LB2772/2005/G2P[4]
 RVA/Human-wt/AUS/CK20048/2011/G2P[4]
 RVA/Human-wt/ITA/PA130/2010/G2P[4]
 RVA/Human-wt/BRA/ES16238/2009/G2P[4]
 RVA/Human-wt/ITA/PA133/2011/G2P[4]
 RVA/Human-wt/BRA/SC19868/2011/G2P[4]
 RVA/Human-wt/BRA/SE19300/2010/G2P[4]
 RVA/Human-wt/ITA/PA83/2007/G2P[4]
 RVA/Human-wt/AUS/CK20024/2006/G2P[4]
 RVA/Human-wt/AUS/CK20026/2006/G2P[4]
 RVA/Human-wt/AUS/CK20029/2006/G2P[4]
 RVA/Human-wt/CHN/TB-Chen/1996/G2P[4]
 RVA/Human-tc/USA/DS-1/1976/G2P[4]
 RVA/Human-tc/KEN/AK26/1982/G2P[4]
 RVA/Human-tc/PHL/L26/1987/G12P[4]
 RVA/Human-wt/ITA/PAI11/1996/G2P[4]
 RVA/Human-wt/BRA/RJ5619/2002/G2P[4]
T2
 RVA/Human-tc/CHN/L621/2006/G3P[9]
 RVA/Human-tc/USA/Wa/1974/G1P[8]
99
77
93
91
100
97
89
76
99
78
98
87
97
95
74
0.05
 RVA/Human-wt/USA/2007719874/2007/G2P[4]
 RVA/Human-wt/USA/VU06-07-36/2006/G2P[4]
 RVA/Human-wt/BRA/MS11142/2005/G2P[4]
 RVA/Human-wt/THA/CU473-BK/2009/G2P[4]
 RVA/Human-wt/USA/LB2772/2005/G2P[4]
 RVA/Human-wt/THA/CU438-KK/2009/G2P[4]
 RVA/Human-wt/THA/CU436-KK/2009/G2P[4]
 RVA/Human-wt/AUS/CK20036/2007/G2P[4]
 RVA/Human-wt/ITA/PA150/2006/G2P[4]
 RVA/Human-wt/BRA/RS13086/2006/G2P[4]
 RVA/Human-wt/BRA/14397 07MG/2007/G2P[4]
 RVA/Human-wt/BRA/MA14286/2007/G2P[4]
 RVA/Human-wt/BRA/12585 06ES/2006/G2P[4]
 RVA/Human-wt/BRA/11143 05MS/2005/G2P[4]
 RVA/Human-wt/BRA/11257 05MS/2005/G2P[4]
 RVA/Human-wt/BRA/12540 06RJ/2006/G2P[4]
 RVA/Human-wt/BRA/12522 06BA/2006/G2P[4]
 RVA/Human-wt/BRA/11782 05RJ/2005/G2P[4]
 RVA/Human-wt/USA/VU10-11-21/2011/G2P[4]
 RVA/Human-wt/BGD/MMC88/2005/G2P[4]
 RVA/Human-wt/BRA/13891 07RJ/2007/G2P[4]
 RVA/Human-wt/BRA/12343 06RJ/2006/G2P[4]
 RVA/Human-wt/BRA/12647 06RJ/2006/G2P[4]
 RVA/Human-wt/BRA/13663 07AL/2007/G2P[4]
 RVA/Human-wt/BRA/14255 07RJ/2007/G2P[4]
 RVA/Human-wt/BRA/14426 07ES/2007/G2P[4]
 RVA/Human-wt/BRA/SE13801/2007/G2P[4]
 RVA/Human-wt/BRA/14919 08RS/2008/G2P[4]
 RVA/Human-wt/BRA/15988 08BA/2008/G2P[4]
 RVA/Human-wt/BRA/MA19557/2011/G2P[4]
 RVA/Human-wt/BRA/RJ12225/2006/G2P[4]
 RVA/Human-wt/BRA/RJ17745/2010/G2P[4]
 RVA/Human-wt/BRA/15811 08SE/2008/G2P[4]
 RVA/Human-wt/BRA/RS15851/2008/G2P[4]
 RVA/Human-wt/BGD/MMC6/2005/G2P[4]
 RVA/Human-wt/AUS/CK20024/2006/G2P[4]
 RVA/Human-wt/AUS/CK20026/2006/G2P[4]
 RVA/Human-wt/BRA/SC19868/2011/G2P[4]
 RVA/Human-wt/BRA/SE19300/2010/G2P[4]
 RVA/Human-wt/RUS/Nov04-H676/2004/G2P[4]
 RVA/Human-xx/RUS/N.N.12698/XXXX/G2P[4]
 RVA/Human-wt/ITA/PA83/2007/G2P[4]
 RVA/Human-wt/ZAF/MRC-DPRU1061/2009/G2P[4]
 RVA/human-wt/JPN/OH3625/2012/G1P[8]
 RVA/Human-wt/ITA/PA133/2011/G2P[4]
 RVA/Human-wt/BRA/16101 09ES/2009/G2P[4]
 RVA/Human-wt/BRA/ES16238/2009/G2P[4]
 RVA/Human-wt/BRA/15900 08MG/2008/G2P[4]
 RVA/Human-wt/BRA/15859 08MG/2008/G2P[4]
 RVA/Human-wt/AUS/CK20040/2010/G2P[4]
 RVA/Human-wt/ITA/PA84/2008/G2P[4]
 RVA/Human-wt/BRA/15782 08MG/2008/G2P[4]
 RVA/Human-wt/BRA/15860 08RJ/2008/G2P[4]
 RVA/Human-wt/RUS/Omsk08-475/2008/G2P[4]
 RVA/Human-wt/BRA/15898 08MG/2008/G2P[4]
 RVA/Human-wt/USA/VU10-11-19/2011/G2P[4]
 RVA/Human-wt/USA/VU10-11-24/2011/G2P[4]
E2
 RVA/Human-tc/USA/Wa/1974/G1P[8]
 RVA/Human-tc/CHN/L621/2006/G3P[9]
100
100
100
87
98
100 84
89
94
0.05
 RVA/Human-wt/ITA/PAI11/1996/G2P[4]
 RVA/Human-wt/BRA/RJ5619/2002/G2P[4]
 RVA/Human-tc/KEN/AK26/1982/G2P[4]
 RVA/Human-tc/USA/DS-1/1976/G2P[4]
 RVA/Human-tc/JPN/KUN/1980/G2P[4]
 RVA/Human-wt/CHN/TB-Chen/1996/G2P[4]
 RVA/Human-wt/AUS/336190/2004/G2P[4]
 RVA/Human-wt/USA/LB2764/2005-06/G2P[4]
 RVA/Human-wt/USA/VU05-06-45/2005/G2P[4]
 RVA/Human-wt/THA/CU209-KK/2008/G2P[4]
 RVA/Human-wt/THA/CMH054/2005/G2P[4]
 RVA/Human-wt/ITA/PA130/2010/G2P[4]
 RVA/Human-wt/BRA/SC19868/2011/G2P[4]
 RVA/Human-wt/AUS/CK20025/2006/G2P[4]
 RVA/Human-wt/AUS/CK20032/2006/G2P[4]
 RVA/Human-wt/AUS/CK20035/2006/G2P[4]
 RVA/Human-wt/ITA/PA83/2007/G2P[4]
 RVA/Human-wt/BRA/SE19300/2010/G2P[4]
 RVA/Human-wt/AUS/V233/1999/G2P[4]
 RVA/Human-wt/ITA/PA150/2006/G2P[4]
 RVA/Human-wt/BRA/MA19557/2011/G2P[4]
 RVA/Human-wt/BRA/RS15851/2008/G2P[4]
 RVA/Human-wt/BRA/SE13801/2007/G2P[4]
 RVA/Human-wt/BRA/RJ12225/2006/G2P[4]
 RVA/Human-wt/AUS/CK20036/2007/G2P[4]
 RVA/Human-wt/BRA/MS11142/2005/G2P[4]
 RVA/Human-wt/USA/VU05-06-66/2005/G2P[4]
 RVA/Human-wt/BRA/RS13086/2006/G2P[4]
 RVA/Human-wt/USA/VU10-11-21/2011/G2P[4]
 RVA/Human-wt/PRY/1463SR/2006/G2G9P[4]
 RVA/Human-wt/PRY/1040SR/2005/G2P[4]
 RVA/Human-wt/BRA/MA14286/2007/G2P[4]
 RVA/Human-wt/USA/LB2772/2005/G2P[4]
 RVA/Human-wt/USA/LB2744/2005/G2P[4]
 RVA/Human-wt/BRA/ES16238/2009/G2P[4]
 RVA/Human-wt/USA/2007719869/2007/G2P[4]
 RVA/Human-wt/BRA/RJ17745/2010/G2P[4]
 RVA/Human-wt/USA/VU10-11-24/2011/G2P[4]
 RVA/Human-wt/ITA/PA133/2011/G2P[4]
 RVA/Human-wt/AUS/CK20054/2010/G2P[4]
 RVA/Human-wt/USA/VU08-09-11/2008/G2P[4]
 RVA/Human-wt/BGD/MMC88/2005/G2P[4]
 RVA/Human-wt/ITA/PA108/2007/G2P[4]
 RVA/Human-wt/BGD/MMC6/2005/G2P[4]
 RVA/Human-wt/USA/VU10-11-19/2011/G2P[4]
H2
 RVA/Human-tc/USA/Wa/1974/G1P[8]
 RVA/Human-tc/CHN/L621/2006/G3P[9]
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Fig. 4. Phylogenetic analyses based on NSP1-5 nucleotide sequences from Brazilian G2P[4] strains detected between 2005 and 2011, and group A rotavirus (RVA) strains
available from GenBank. Brazilian G2P[4] strains analyzed in the current study are marked with a ﬁlled circle (vaccinated) and a ﬁlled triangle (non-vaccinated). Bootstrap
values under 70% are not shown. Genotypes are shown at the right-hand side of each phylogenetic tree. Scale bars represent 0.05 nucleotide substitution per site.
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in orange), showed different phylogenetic pattern comparing with
strains colored in red (Figs. 4 and 5).
Phylogenetic analysis based on NSP1-3, NSP5, VP1-4, and VP6
obtained sequences revealed that strain RVA/Human-wt/BRA/
ES16238/2009/G2P[4] (colored in blue) was closely related with
RVA/Human-wt/ITA/PA133/2011/G2P[4] strain (Figs. 4 and 5).
Depending on the analyzed encoding gene, this strain showed clo-
sely phylogenetic relationship with other human G2P[4] strains.
For the NSP1 and NSP5 encoding gene this Brazilian strain grouped
together with RVA/Human-wt/BRA/RJ17745/2010/G2P[4]; for the
NSP3, with RVA/Human-wt/BRA/SE19300/2010/G2P[4] and RVA/
Human-wt/BRA/SC19868/2011/G2P[4]; and for VP4 with RVA/
Human-wt/BRA/SE19300/2010/G2P[4] strain (Figs. 4 and 5). For
the NSP4 encoding gene strain RVA/Human-wt/BRA/ES16238/
2009/G2P[4] showed close phylogenetic relationship with previous
Brazilian detected strains (2008–2010). Phylogenetic analysis
based on VP3 showed that strain RVA/Human-wt/BRA/ES16238/
2009/G2P[4] was closely related with RVA/Human-wt/ITA/PA133/
2011/G2P[4] strain, strains detected in Bangladesh (2005), Thai-
land (2008), Australia (2010), USA (2011), and showed 97% of
nucleotide identity with a caprine strain detected in 1999 (Fig. 5).
Strain RVA/Human-wt/BRA/RJ17745/2010/G2P[4] (colored in
orange) was closely related to strain RVA/Human-wt/USA/
2007719869/2007/G2P[4]. Depending on the encoding gene, clo-
sely related strains were human G2P[4] strains (Figs. 4 and 5).For the NSP4 encoding gene this strain showed close phylogenetic
relationship with previous Brazilian detected strains (2006–2008
and in 2010).
RVA Brazilian strains RVA/Human-wt/BRA/SE19300/2010/
G2P[4] (colored in blue) and RVA/Human-wt/BRA/SC19868/2011/
G2P[4] (colored in red) grouped together for the NSP2-5, VP3 and
VP6 encoding genes (Figs. 4 and 5). For NSP1, VP2 and VP4, strain
RVA/Human-wt/BRA/SC19868/2011/G2P[4] grouped together with
other Brazilian strains (2005–2008, 2011) (colored in red) (Figs. 4
and 5). Phylogenetic analysis based on VP1 revealed that strain
RVA/Human-wt/BRA/SC19868/2011/G2P[4] grouped together with
human G2P[4] strains detected in Australia (2006) and Italy (2007),
and a caprine G6P[1] strain detected in 1999, showing 97% of
nucleotide identity (Fig. 5).
The VP2 sequence of strain RVA/Human-wt/BRA/SE19300/
2010/G2P[4] could not be obtained, despite repeated attempts.
Partial sequences of VP1 encoding gene were obtained for RVA/
Human-wt/BRA/RS13086/2006/G2P[4], RVA/Human-wt/BRA/
SE13801/2007/G2P[4], RVA/Human-wt/BRA/RS15851/2008/
G2P[4], RVA/Human-wt/BRA/SE19300/2010/G2P[4] strains.
Analysis of VP1-4, VP6 and NSP1-5 sequences showed that
G2P[4] Brazilian strains shared between 87.3–100%, and 93–100%
of nucleotide and amino acid identity values, respectively (Table 2).
Strain RVA/Human-wt/BRA/ES16238/2009/G2P[4] differed more
than 10% comparing with other Brazilian strains analyzed in the
current study for NSP4 and VP3 encoding genes (data not shown).
 RVA/Human-xx/AUS/MON008/2010/G2P[4]
 RVA/Human-wt/USA/VU10-11-19/2011/G2P[4]
 RVA/Human-wt/THA/CU110-BK/2008/G2P[4]
 RVA/Human-wt/USA/VU08-09-11/2008/G2P[4]
 RVA/Human-wt/USA/VU08-09-8/2008/G2P[4]
 RVA/Human-wt/BRA/ES16238/2009/G2P[4]
 RVA/Human-wt/ITA/PA133/2011/G2P[4]
 RVA/Human/AUS/WAPC703/2010/G2P[4]
 RVA/Human-wt/BRA/RJ17745/2010/G2P[4]
 RVA/Human-wt/USA/2007719869/2007/G2P[4]
 RVA/Human-wt/AUS/SA066/2010/G2P[4]
 RVA/Human-wt/USA/LB1562/2010/G9P[4]
 RVA/Human-wt/USA/VU05-06-45/2005/G2P[4]
 RVA/Human-wt/ITA/PA17/2008/G2P[4]
 RVA/Human-wt/USA/VU10-11-24/2011/G2P[4]
 RVA/Goat-wt/BGD/GO34/1999/G6P[1]
 RVA/Human-wt/ITA/PA83/2007/G2P[4]
 RVA/Human-wt/BRA/SC19868/2011/G2P[4]
 RVA/Human-wt/AUS/CK20031/2006/G2P[4]
 RVA/Human-wt/AUS/CK20026/2006/G2P[4]
 RVA/Human-wt/AUS/CK20015/2000/G2P[4]
 RVA/Human-wt/USA/VU10-11-21/2011/G2P[4]
 RVA/Human-wt/AUS/V233/1999/G2P[4]
 RVA/Human-wt/ITA/PA150/2006/G2P[4]
 RVA/Human-wt/USA/VU06-07-36/2006/G2P[4]
 RVA/Human-wt/USA/2007719874/2007/G2P[4]
 RVA/Human-wt/THA/CU473-BK/2009/G2P[4]
 RVA/Human-wt/THA/CU497-BK/2009/G2P[4]
 RVA/Human-wt/AUS/CK20036/2007/G2P[4]
 RVA/Human-wt/USA/VU05-06-66/2005/G2P[4]
 RVA/Human-wt/BRA/MA14286/2007/G2P[4]
 RVA/Human-wt/BRA/RJ12225/2006/G2P[4]
 RVA/Human-wt/BRA/MS11142/2005/G2P[4]
 RVA/Human-wt/BRA/MA19557/2011/G2P[4]
 RVA/Human-wt/BRA/RS15851/2008/G2P[4]
 RVA/Human-tc/USA/DS-1/1976/G2P[4]
 RVA/Human-wt/CHN/TB-Chen/1996/G2P[4]
R2
 RVA/Human-tc/USA/Wa/1974/G1P[8]
 RVA/Human-tc/CHN/L621/2006/G3P[9]
100
100
90
100
100
94
90
99
97
100
76
82
100
96
100
100
95
8399
82
90
0.05
 RVA/Human-wt/BRA/RJ12225/2006/G2P[4]
 RVA/Human-wt/BRA/MS11142/2005/G2P[4]
 RVA/Human-wt/BRA/SE13801/2007/G2P[4]
 RVA/Human-wt/BRA/MA19557/2011/G2P[4]
 RVA/Human-wt/BRA/RS15851/2008/G2P[4]
 RVA/Human-wt/USA/2007719874/2007/G2P[4]
 RVA/Human-wt/BRA/MA14286/2007/G2P[4]
 RVA/Human-wt/BRA/RS13086/2006/G2P[4]
 RVA/Human-wt/USA/LB2744/2005/G2P[4]
 RVA/Human-wt/USA/VU05-06-66/2005/G2P[4]
 RVA/Human-wt/USA/LB2772/2005/G2P[4]
 RVA/Human-wt/ITA/PA150/2006/G2P[4]
 RVA/Human-wt/AUS/CK20036/2007/G2P[4]
 RVA/Human-wt/AUS/CK20013/2000/G2P[4]
 RVA/Human-wt/ITA/PA84/2008/G2P[4]
 RVA/Human-wt/ITA/PA3/2004/G2P[4]
 RVA/Human-wt/USA/VU10-11-21/2011/G2P[4]
 RVA/Human-wt/AUS/CK20034/2006/G2P[4]
 RVA/Human-wt/THA/CU438-KK/2009/G2P[4]
 RVA/Human-wt/AUS/V203/2009/G2P[4]
 RVA/Human-wt/AUS/CK20047/2011/G2P[4]
 RVA/Human-wt/ITA/PA83/2007/G2P[4]
 RVA/Human-wt/AUS/CK20032/2006/G2P[4]
 RVA/Human-wt/BRA/SC19868/2011/G2P[4]
 RVA/Human-wt/BRA/SE19300/2010/G2P[4]
 RVA/Human-wt/USA/2007719869/2007/G2P[4]
 RVA/Human-wt/BRA/RJ17745/2010/G2P[4]
 RVA/Human-wt/USA/VU05-06-54/2005/G2P[4]
 RVA/Human-wt/BGD/MMC6/2005/G2P[4]
 RVA/Human-wt/THA/CU209-KK/2008/G2P[4]
 RVA/Human-wt/USA/VU05-06-45/2005/G2P[4]
 RVA/Human-wt/ITA/PA17/2008/G2P[4]
 RVA/Human-wt/ITA/PA108/2007/G2P[4]
 RVA/Human-wt/USA/VU08-09-38/2008/G2P[4]
 RVA/Human-xx/AUS/WAPC703/2010/G2P[4]
 RVA/Human-wt/USA/VU10-11-24/2011/G2P[4]
 RVA/Human-wt/CHN/TB-Chen/1996/G2P[4]
 RVA/Human-tc/USA/DS-1/1976/G2P[4]
 RVA/Goat-wt/BGD/GO34/1999/G6P[1]
 RVA/Human-wt/ITA/PA133/2011/G2P[4]
 RVA/Human-wt/BRA/ES16238/2009/G2P[4]
 RVA/Human-wt/AUS/SA066/2010/G2P[4]
 RVA/Human-wt/AUS/CK20044/2010/G2P[4]
 RVA/Human-wt/BGD/MMC88/2005/G2P[4]
 RVA/Human-wt/THA/CU110-BK/2008/G2P[4]
 RVA/Human-xx/AUS/MON008/2010/G2P[4]
 RVA/Human-wt/USA/VU10-11-19/2011/G2P[4]
M2
 RVA/Human-tc/USA/Wa/1974/G1P[8]
 RVA/Human-tc/CHN/L621/2006/G3P[9]
100
95
100
100
100
100
100
97
100
89
99
88
86
89
78
99
100
99
88
89
91
85100
85
98
100
83
0.05
 RVA/Human-wt/BRA/SE13801/2007/G2P[4]
 RVA/Human-wt/BRA/RJ12225/2006/G2P[4]
 RVA/Human-wt/BRA/RS13086/2006/G2P[4]
 RVA/Human-wt/BRA/MA14286/2007/G2P[4]
 RVA/Human-wt/THA/CU438-KK/2009/G2P[4]
 RVA/Human-wt/THA/CU436-KK/2009/G2P[4]
 RVA/Human-wt/USA/VU05-06-66/2005/G2P[4]
 RVA/Human-wt/USA/LB2772/2005/G2P[4]
 RVA/Human-wt/BRA/MS11142/2005/G2P[4]
 RVA/Human-wt/AUS/CK20036/2007/G2P[4]
 RVA/Human-wt/BRA/SC19868/2011/G2P[4]
 RVA/Human-wt/BRA/RS15851/2008/G2P[4]
 RVA/Human-wt/BRA/MA19557/2011/G2P[4]
 RVA/Human-wt/ITA/PA150/2006/G2P[4]
 RVA/Human-wt/USA/VU10-11-21/2011/G2P[4]
 RVA/Human-wt/AUS/V233/1999/G2P[4]
 RVA/Human-wt/ZAFGR10924/1999/G9P[6]
 RVA/Human-wt/ZAF/MRC-DPRU9317/1999/G9P[6]
 RVA/Human-wt/USA/VU10-11-19/2011/G2P[4]
 RVA/Human-wt/THA/CU110-BK/2008/G2P[4]
 RVA/Human-wt/ITA/PA108/2007/G2P[4]
 RVA/Human-wt/BGD/ MMC88/2005/G2P[4]
 RVA/Human-wt/AUS/SA066/2010/G2P[4]
 RVA/Human-wt/USA/VU08-09-13/2008/G2P[4]
 RVA/Human-wt/USA/VU10-11-24/2011/G2P[4]
 RVA/Human-wt/ITA/PA133/2011/G2P[4]
 RVA/Human-wt/ITA/PA133/2011/G2P[4]
 RVA/Human-wt/BGD/RV161/2000/G12P[6]
 RVA/Human-wt/USA/VU05-06-54/2005/G2P[4]
 RVA/Human-xx/AUS/WAPC703/2010/G2P[4]
 RVA/Human-wt/AUS/CK20051/2010/G2P[4]
 RVA/Human-wt/USA/2007719869/2007/G2P[4]
 RVA/Human-wt/BRA/RJ17745/2010/G2P[4]
 RVA/Human-wt/CHN/TB-Chen/1996/G2P[4]
 RVA/Human-tc/USA/DS-1/1976/G2P[4]
 RVA/Human-wt/ITA/PAI11/1996/G2P[4]
 RVA/Human-tc/KEN/AK26/1982/G2P[4]
C2
 RVA/Human-tc/USA/Wa/1974/G1P[8]
 RVA/Human-tc/CHN/L621/2006/G3P[9]
100
99
100
92
100
90
99
75
79
92
97
99
97
95
99
100
83
97
7697
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 RVA/Human-wt/BRA/SE13801/2007/G2P[4]
 RVA/Human-wt/BRA/RJ12225/2006/G2P[4]
 RVA/Human-wt/BRA/MS11142/2005/G2P[4]
 RVA/Human-wt/BRA/RS13086/2006/G2P[4]
 RVA/Human-wt/BRA/RS15851/2008/G2P[4]
 RVA/Human-wt/BRA/MA19557/2011/G2P[4]
 RVA/Human-wt/BRA/MA14286/2007/G2P[4]
 RVA/Human-wt/USA/LB2744/2005/G2P[4]
 RVA/Human-wt/BRA/SC19868/2011/G2P[4]
 RVA/Human-wt/USA/VU10-11-21/2011/G2P[4]
 RVA/Human-wt/THA/CU473-BK/2009/G2P[4]
 RVA/Human-wt/AUS/CK20034/2006/G2P[4]
 RVA/Human-wt/AUS/CK20036/2007/G2P[4]
 RVA/Human-wt/USA/2007719874/2007/G2P[4]
 RVA/Human-wt/USA/VU06-07-36/2006/G2P[4]
 RVA/Human-wt/ITA/PA150/2006/G2P[4]
 RVA/Human-wt/AUS/CK20012/2000/G2P[4]
 RVA/Human-wt/AUS/CK20013/2000/G2P[4]
 RVA/Human-wt/USA/VU10-11-24/2011/G2P[4]
 RVA/Human-wt/BRA/RJ17745/2010/G2P[4]
 RVA/Human-wt/USA/2007719869/2007/G2P[4]
 RVA/Human-wt/BGD/SK138/2004/G2P[4]
 RVA/Human-wt/ITA/PA17/2008/G2P[4]
 RVA/Human-wt/USA/VU10-11-19/2011/G2P[4]
 RVA/Human-wt/USA/VU05-06-45/2005/G2P[4]
 RVA/Human-wt/USA/VU05-06-54/2005/G2P[4]
 RVA/Human-wt/AUS/CK20028/2006/G2P[4]
 RVA/Human-wt/BRA/SE19300/2010/G2P[4]
 RVA/Human-wt/AUS/CK20024/2006/G2P[4]
 RVA/Human-wt/AUS/CK20032/2006/G2P[4]
 RVA/Human-wt/ITA/PA83/2007/G2P[4]
 RVA/Human-wt/BRA/ES16238/2009/G2P[4]
 RVA/Human-wt/BEL/BE1251/2009/G2P[4]
 RVA/Human-wt/ITA/PA133/2011/G2P[4]
 RVA/Human-wt/CHN/TB-Chen/1996/G2P[4]
 RVA/Human-tc/USA/DS-1/1976/G2P[4]
 RVA/Human-wt/BRA/PAI11/1996/G2P[4]
 RVA/Human-tc/KEN/AK26/1982/G2P[4]
 RVA/Human-wt/THA/L26/1987/G12P[4]
 RVA/Human-wt/MWI/1473/2001/G8P[4]
 RVA/Human-wt/KEN/MRC-DPRU1606/2009/G8P[4]
 RVA/Human-wt/ZMB/MRC-DPRU1621/2008/G8P[4]
P[4]
 RVA/Vaccine/USA/Rotarix-A41CB052A/1988/G1P[8]
 RVA/Human-wt/BGD/N26/2002/G12P[6]
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100
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100
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99
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 RVA/Human-wt/BRA/16099 09ES/2009/G2P[4]
 RVA/Human-wt/BRA/16100 09ES/2009/G2P[4]
 RVA/Human-wt/BRA/15900 08MG/2008/G2P[4]
 RVA/Human-wt/BRA/ES16238/2009/G2P[4]
 RVA/Human-wt/BRA/15782 08MG/2008/G2P[4]
 RVA/Human-wt/BRA/15860 08RJ/2008/G2P[4]
 RVA/Human-wt/ITA/PA133/2011/G2P[4]
 RVA/Human-wt/USA/VU10-11-19/2011/G2P[4]
 RVA/Human-wt/THA/CMH030/2007/G2P[4]
 RVA/Human-wt/BGD/MMC88/2005/G2P[4]
 RVA/Human-wt/ITA/PA108/2007/G2P[4]
 RVA/Human-wt/USA/VU05-06-54/2005/G2P[4]
 RVA/Human-wt/USA/LB2764/2005-06/G2P[4]
 RVA/Human-wt/RUS/Nov09-D2/2009/G2P[4]
 RVA/Human-wt/BRA/RJ17745/2010/G2P[4]
 RVA/Human-wt/USA/2007719869/2007/G2P[4]
 RVA/Human-wt/USA/VU10-11-24/2011/G2P[4]
 RVA/Human-wt/BRA/15863 08MA/2008/G2P[4]
 RVA/Human-wt/BRA/15988 08BA/2008/G2P[4]
 RVA/Human-wt/BRA/SE13801/2007/G2P[4]
 RVA/Human-wt/BRA/15894 08ES/2008/G2P[4]
 RVA/Human-wt/BRA/15777 08PE/2008/G2P[4]
 RVA/Human-wt/BRA/13891 07RJ/2007/G2P[4]
 RVA/Human-wt/BRA/13793 07SE/2007/G2P[4]
 RVA/Human-wt/BRA/13663 07AL/2007/G2P[4]
 RVA/Human-wt/BRA/RJ12225/2006/G2P[4]
 RVA/Human-wt/BRA/13151 06RJ/2006/G2P[4]
 RVA/Human-wt/BRA/SC19868/2011/G2P[4]
 RVA/Human-wt/BRA/SE19300/2010/G2P[4]
 RVA/Human-wt/RUS/Nov06-1283/2006/G2P[4]
 RVA/Human-wt/RUS/Nov05-137/2005/G2P[4]
 RVA/Human-wt/RUS/Omsk07-87/2007/G2P[4]
 RVA/Human-wt/RUS/Omsk08-418/2008/G2P[4]
 RVA/Human-wt/ITA/PA83/2007/G2P[4]
 RVA/Human-wt/AUS/CK20032/2006/G2P[4]
 RVA/Human-wt/AUS/CK20031/2006/G2P[4]
 RVA/Human-wt/USA/VU10-11-21/2011/G2P[4]
 RVA/Human-wt/ITA/PA150/2006/G2P[4]
 RVA/Human-wt/USA/VU06-07-36/2006/G2P[4]
 RVA/Human-wt/AUS/CK20036/2007/G2P[4]
 RVA/Human-wt/BRA/15811 08SE/2008/G2P[4]
 RVA/Human-wt/BRA/15840 08RS/2008/G2P[4]
 RVA/Human-wt/BRA/RS15851/2008/G2P[4]
 RVA/Human-wt/BRA/MA19557/2011/G2P[4]
 RVA/Human-wt/BRA/MS11142/2005/G2P[4]
 RVA/Human-wt/USA/LB2744/2005/G2P[4]
 RVA/Human-wt/BRA/15771 08PE/2008/G2P[4]
 RVA/Human-wt/BRA/14397 07MA/2007/G2P[4]
 RVA/Human-wt/BRA/RS13086/2006/G2P[4]
 RVA/Human-wt/BRA/MA14286/2007/G2P[4]
 RVA/Human-wt/BRA/13039 06RS/2006/G2P[4]
 RVA/Human-wt/ITA/PAI11/1996/G2P[4]
 RVA/Human-tc/USA/DS-1/1976/G2P[4]
 RVA/Human-wt/AUS/CK20001/1977/G2P[4]
 RVA/Human-tc/JPN/S2/1980/G2P[4]
 RVA/Human-wt/CHN/TB-Chen/1996/G2P[4]
I2
 RVA/Human-tc/CHN/L621/2006/G3P[9]
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Fig. 5. Phylogenetic analyses based on VP1-4, and VP6 nucleotide sequences from Brazilian G2P[4] strains detected between 2005 and 2011, and group A rotavirus (RVA)
strains available from GenBank. Brazilian G2P[4] strains analyzed in the current study are marked with a ﬁlled circle (vaccinated) and a ﬁlled triangle (non-vaccinated).
Bootstrap values under 70% are not shown. Genotypes are shown at the right-hand side of each phylogenetic tree. Scale bars represent 0.05 nucleotide substitution per site.
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G2P[4] has been the most common genotype detected in Brazil
after the onset of RV1 mass vaccination (Gurgel et al., 2007; de
Oliveira et al., 2008; Nakagomi et al., 2008; Leite et al., 2008;
Carvalho-Costa et al., 2009, 2005; da Silva Soares et al., 2014).
The emergence of this genotype has motivated a great discussion
and a relationship between this phenomenon and RV1 vaccination
has been proposed suggesting that universal vaccination would
have exerted selective pressure on circulating RVAs, selecting
G2P[4] (Gurgel et al., 2007; Nakagomi et al., 2008; Matthijnssens
et al., 2012).
The results obtained in the current study demonstrate that the
detection rate of G2P[4] in RVA positive samples has been high in
the years after the introduction of mass vaccination with RV1.
With the exception of 2009 this rate has been above 50%,
reaching 87% in 2010. G2P[4] has also been frequently detected
in children vaccinated with RV1. The drop in the detection rate
of G2P[4] in 2009 was associated with an overall reduction in
detection rates of RVA in Brazil and with an increase in the rela-
tive detection of G1, G3 and G9, as well as P[6] in some regions of
the country. In this context, the RVA season in 2009 was of low
intensity. In this period, it was believed that the circulation of
G2 could have gotten into the exhaustion phase (Carvalho-Costa
et al., 2005), which was not conﬁrmed in 2010 and 2011, when
this genotype was again frequently detected. We examine in
more detail the geographical location of G2P[4] positive samples,
trying to identify a route of spread of this genotype during its
process of emergence in Brazil. A very low rate of G2P[4]detection between 2001 and 2004 was obtained from RVA-sur-
veillance performed in RRRL-LVCA. In the present survey, we con-
ﬁrmed that G2P[4] was absent in the RVA positive samples
studied in the ﬁrst semester of 2005. In this year, the ﬁrst cities
in which G2P[4] was detected are located in Western Brazil.
Throughout 2005, G2P[4] continued to be detected in this region
and in Amazonian Brazil, being absent from the most populous
Brazilian regions of the Atlantic coast. Only in December 2005,
G2P[4] was detected in the main Brazilian cities in Eastern Brazil,
speciﬁcally in Rio de Janeiro. Universal vaccination against RVA
began in March 2006 and, starting this year, G2P[4] was detected
early in all monitored regions, in a phase in which the cohort of
vaccinated children was still very limited.
Analysis of the VP7 and VP8⁄ encoding genes showed that Bra-
zilian G2P[4] strains identiﬁed in vaccinated and unvaccinated
children grouped together in the same genetic clusters, and
revealed that contemporary G2P[4] strains (circulating from 2005
to 2011) belonged to distinct lineages from the reference strain
DS-1 and the SC2-9 G2-reassortant strain of RV5, as previously
reported (Fig. 2) (Doan et al., 2011; Gómez et al., 2005; Zeller
et al., 2012; Mouna et al., 2013; Do et al., 2014; Donato et al.,
2010; Giammanco et al., 2014). Comparison of the RV1 amino acid
sequences inside previous described antigenic epitopes in VP7 and
VP8⁄, with Brazilian G2P[4] strains revealed several amino acid dif-
ferences as expected since G2 is rather divergent from G1 strains
(Fig. 3). The same differences have been previously described in
G2P[4] strains detected in other countries (Zeller et al., 2012;
Mouna et al., 2013). In addition, most of the differences observed
have been maintained in the Brazilian strains along the sampling
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Regarding the G2 VP7 gene of RV5 strain, phylogenetic analysis
showed that Brazilian G2P[4] strains did not share a close phyloge-
netic relationship with RV5 strain, and many amino acid
differences were observed inside antigenic epitopes as previously
observed in Belgium, Tunisia, and Australia (Figs. 2 and 3) (Zeller
et al., 2012; Mouna et al., 2013; Donato et al., 2010). This data sug-
gest that the same genetic variants of RVA genotype G2P[4] VP7
and VP8⁄ proteins have been circulating in the population world-
wide in the last decade, but whether amino acid differences
observed inside antigenic epitopes resulted in a reduced vaccine
efﬁcacy remains to be investigated.
The analysis of the genomic background of G2P[4] strains
identiﬁed throughout the process of implementation of mass
immunization with RV1 may be useful to clarify its potential role
on observed changes in the distribution of RVA genotypes which
occurred between 2005 and 2011 in Brazil. The analysis of the
genomic background of eleven Brazilian G2P[4] RVA strains ana-
lyzed in the current study revealed a complete DS-1-like back-
ground, and genetic variants were observed circulating in the
Brazilian population (Figs. 4 and 5). Differently from what was
recently observed by Dennis et al. (2014), phylogenetic analyses
of G2P[4] Brazilian RVA strains based on NSP1-5, VP1-4, and
VP6 showed different clustering patterns (Figs. 4 and 5) suggest-
ing the occurrence of reassortment events among strains. This
discrepancy with the results from Dennis et al. (2014) and results
obtained in our study might be related with the fact that samples
analyzed in the current study were detected in different Brazilian
regions, sometimes geographically distant, and strains detected
during a relatively long time period were analyzed (2005–
2011). On the other hand, similar results regarding NSP4 and
VP3 encoding gene were observed for Brazilian G2P[4] strains,
these two genes were the most divergent among the eleven
RVA genes (Figs. 4 and 5). With the exception of VP1 and VP3
encoding genes, G2P[4] Brazilian strains were all closely related
to other human RVA strains. Strains RVA/Human-wt/BRA/
SC19868/2011/G2P[4] (for VP1) and RVA/Human-wt/BRA/
ES16238/2009/G2P[4] (for VP3) showed close phylogenetic rela-
tionship with RVA/Goat-tc/BGD/GO34/1999/G6P[1] animal strain
(97% identity). Similar results were recently described for
G2P[4] RVA strains detected in USA and Italy (Dennis et al.,
2014; Giammanco et al., 2014). As happens in other countries,
available data regarding animal RVA strains is still poor and make
it difﬁcult to study the origin of this kind of animal-like genome
segment incorporation into human RVA strains.
In conclusion, our data suggest that the G2P[4] strains circu-
lating in Brazil during implementation of mass immunization
with RV1 are not separated into genetic clusters deﬁned by
pre and post vaccination periods, suggesting that implementa-
tion of RV1 vaccination might not inﬂuence the genetic diversity
observed among analyzed strains. Furthermore, Brazilian G2P[4]
strains are closely related with human G2P[4] strains circulating
in other countries, some of which had not yet implemented uni-
versal vaccination against RVA. A possible hypothesis is that the
introduction of RV1 vaccine into the NIP has helped to decrease
the prevalence of predominant Wa-like strains facilitating the
increase of the heterotypic (DS-1-like) RVA strain G2P[4] in the
Brazilian population. In addition, the long period of low or no
circulation of genotype G2P[4] in Brazil previous to RV1 intro-
duction would have created favorable conditions for the accumu-
lation of immunological susceptible individuals (Carvalho-Costa
et al., 2009; Assis et al., 2013). These facts, together with the
genetic diversity found in different geographical regions
throughout the years before, and after the introduction of the
vaccine might explained the high prevalence of genotype
G2P[4] in Brazil since 2005.Acknowledgments
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